Latest Listings And Ipos News

Nanoveu Limited’s transformative half-year report highlights its EMASS acquisition, executive hires, and technology advances amid a $3 million loss and new US OTCQB listing.

Excelsior Capital reported a sharp fall in net profit after tax for FY25 despite a 74% rise in investment income, reflecting the absence of last year’s one-off asset sale gain. The company declared a higher fully franked final dividend, signalling confidence in its portfolio.

TerraCom Limited reported a statutory loss of A$33.7 million for FY2025 amid lower coal sales and prices, while progressing its Moorlands Thermal Coal Project in partnership with Wintime Energy Group.

Clime Investment Management Limited has reported a significant turnaround in FY25, returning to profitability with a 13% revenue increase and proposing a fully franked final dividend. The company expanded its business lines and strengthened its leadership team, setting a positive outlook for FY26.

Astron Limited has finalized its move from Hong Kong to Australia, issuing new securities on a two-for-one basis and preparing for ASX trading starting September 1, 2025.

Decidr AI Industries Ltd has reported a dramatic turnaround with a $71.1 million profit for FY2025, driven by its strategic acquisition of Decidr.ai Pty Ltd. The company is now moving to acquire full ownership of Decidr.ai, signaling a bold push into AI software.

Perpetual Resources has launched a prospectus to enable trading of new options issued alongside a recent $1.6 million placement, aiming to unlock liquidity while outlining key risks for investors.

AIMS Property Securities Fund (APW) reported a remarkable financial year ending June 2025, with net income and revenue more than doubling and net tangible assets per unit rising 31.8%. The fund’s conservative, debt-free approach and diversified portfolio helped it outperform the broader market despite ongoing distribution suspensions.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Wellnex Life reported a strong 40.4% revenue increase to $23.6 million in FY25, alongside a 57% improvement in normalised EBITDA loss, signaling progress despite ongoing investment costs.

Wellnex Life Limited reported a strong 40% revenue increase in FY25 driven by its Pain Away brand, yet posted a wider loss due to one-off costs and finance expenses. The company’s balance sheet strengthened following a dual AIM listing and debt settlements.

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.